Contributions to Hypertension With Androgen Deprivation Therapy

Inclusion Criteria:

• -age 40+ years;

• resting blood pressure <140/90 mmHg;

• fasted blood glucose <126 mg/dL;

• testosterone ≥400 ng/dL;

• sedentary to recreationally active;

• nonsmokers;

• healthy as determined by medical history, physical exam, blood and urine chemistriesand resting and exercise ECG during a physician supervised graded exercise treadmilltest OR recent diagnosis of non-metastatic prostate cancer with plans to undergoandrogen deprivation therapy;

• PSA <4.00 ng/dL if in the non-cancer group;

• Gleason Score ≤7 if in the prostate cancer group;

• no use of medications that might influence cardiovascular function (e.g.,antihypertensives, lipid-lowering medications);

• willing and able to be on GnRHagonist and AR inhibitor;

• not taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications,or willing to stop use for four weeks prior to the start of the study;

• not using exogenous sex hormones for at least one year

Exclusion Criteria:

• -acute liver disease;

• chronic kidney disease, serum creatinine >1.3 mg/dL, macroalbuminuria >300 mg/g ofproteinuria

• pre-existing or active cardiac, renal or hepatic disease, epilepsy or other seizuredisorder;

• diabetes, active or chronic infection, disease that affects the nervous system;

• Gleason Score ≥8;

• thyroid dysfunction, defined as ultrasensitive TSH <0.5 or >5.0 mU/L, volunteerswith abnormal TSH values will be re-considered for participation after follow-upevaluation by the PCP with initiation or adjustment of thyroid hormone replacement;

• tobacco use within the previous 12 months